Julie A. Vetalice, Author at ORTHOWORLD

NuVasive to Acquire Ellipse Technologies

Competitive Landscape Mergers & Acquisitions

NuVasive entered into a definitive agreement to acquire Ellipse Technologies for US $380MM in cash, with a potential $30MM milestone payable in 2017. The transaction is slated to close in mid-1Q16. Ellipse posted 2015 revenue of ~$40MM, +54% vs. 2014.

Jan 05, 2016

First Spinal Fusion with Single-Step Insertion of DSG Technology-Enabled Screws

ORTHOFLASH Spine

SpineGuard announced the world’s 1st spinal fusion procedure performed with 1-step insertion of pedicle screws guided by Dynamic Surgical Guidance or DSG™ technology.

Jan 05, 2016

Agent Medical Launches ArthroBridge and ArthroMate Lower Extremity Products

ORTHOFLASH Trauma

Agent Medical launched ArthroBridge™, an implant for the treatment of hammertoes, and the ArthroMate™ rasp designed for rear foot fusion procedures.

Jan 05, 2016

Bone Therapeutics Granted Additional EUR 2MM in Funding

Investments The Numbers

Bone Therapeutics was granted an additional 2MM (~US $2.15MM) in non-dilutive funding, bringing the total non-dilutive funding received within 2015 to 5MM.

Jan 05, 2016

Smith+Nephew Completes Acquisition of Blue Belt Technologies

Competitive Landscape Mergers & Acquisitions

Smith+Nephew completed its acquisition of Blue Belt Technologies, developer of the Navio surgical robotics-assistance system for unicondylar knee replacement.

Jan 05, 2016

Ortho Kinematics Raises $4 Million in Debt Financing

Investments The Numbers

Ortho Kinematics closed US $4MM in debt financing. Funds will support global commercialization of the Vertebral Motion Analysis product for radiographic assessment of spinal motion and instability, as well as launch of new product features.

Jan 05, 2016

Bioventus Launches Durolane OA Treatment in Taiwan

Orthobiologics ORTHOFLASH

Bioventus launched DUROLANE® single-injection hyaluronic acid-based osteoarthritis treatment in Taiwan.

Jan 04, 2016

Vericel Submits BLA to FDA for MACI for Treatment of Knee Cartilage Defects

Orthobiologics ORTHOFLASH

Vericel submitted a Biologics License Application to FDA for MACI™ matrix applied characterized autologous cultured chondrocytes, an investigational product intended to treat adult symptomatic cartilage defects of the knee.

Jan 04, 2016

Extremities Market Attracts New Players and Innovation

Competitive Landscape Market Drivers

The extremities market generated worldwide product sales of $6.7 billion in 2014, a 9.5% year-over-year increase driven by the absence of payor scrutiny and company saturation, as well as heightened interest from surgeons and patients, according to ORTHOWORLD estimates.

Oct 01, 2015

The State and Future of the Orthopaedic Industry: A High Altitude View – FDA: The Fly in the Ointment?

Executive Insights Industry Voices

Orthopedics will be more challenging in the future than in the past, but there are opportunities to do well.

Oct 15, 2012

Get the ORTHOWORLD Newsletter!

Contact Us